235 related articles for article (PubMed ID: 19439518)
1. The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy.
Krämer S; Binder E; Loof T; Wang-Rosenke Y; Martini S; Khadzhynov D; Budde K; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2009 Jul; 297(1):F218-27. PubMed ID: 19439518
[TBL] [Abstract][Full Text] [Related]
2. S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis.
Martini S; Krämer S; Loof T; Wang-Rosenke Y; Daig U; Budde K; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2007 Jun; 292(6):F1761-70. PubMed ID: 17356129
[TBL] [Abstract][Full Text] [Related]
3. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis.
Peters H; Martini S; Wang Y; Shimizu F; Kawachi H; Krämer S; Neumayer HH
Kidney Int; 2004 Oct; 66(4):1434-43. PubMed ID: 15458436
[TBL] [Abstract][Full Text] [Related]
4. Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats.
Schaier M; Vorwalder S; Sommerer C; Dikow R; Hug F; Gross ML; Waldherr R; Zeier M
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F769-80. PubMed ID: 19535570
[TBL] [Abstract][Full Text] [Related]
5. FTY720 reduces extracellular matrix expansion associated with ischemia-reperfusion induced injury.
Delbridge MS; Shrestha BM; Raftery AT; El Nahas AM; Haylor J
Transplant Proc; 2007 Dec; 39(10):2992-6. PubMed ID: 18089307
[TBL] [Abstract][Full Text] [Related]
6. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.
Krämer S; Wang-Rosenke Y; Scholl V; Binder E; Loof T; Khadzhynov D; Kawachi H; Shimizu F; Diekmann F; Budde K; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2008 Feb; 294(2):F440-9. PubMed ID: 18094032
[TBL] [Abstract][Full Text] [Related]
7. FTY720 attenuates tubulointerstitial inflammation and fibrosis in subtotally nephrectomized rats.
Ni HF; Chen JF; Zhang MH; Pan MM; Zhang JD; Liu H; Tang RN; Ma KL; Liu BC
Ren Fail; 2013 Aug; 35(7):996-1004. PubMed ID: 23848241
[TBL] [Abstract][Full Text] [Related]
8. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves.
Zhang Z; Zhang ZY; Fauser U; Schluesener HJ
Exp Neurol; 2008 Apr; 210(2):681-90. PubMed ID: 18261728
[TBL] [Abstract][Full Text] [Related]
9. FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia; impact on long-term survival and T-lymphocyte tissue infiltration.
Kaudel CP; Frink M; Schmiddem U; Probst C; Bergmann S; Krettek C; Klempnauer J; van Griensven M; Winkler M
Transplant Proc; 2007 Mar; 39(2):499-502. PubMed ID: 17362767
[TBL] [Abstract][Full Text] [Related]
10. Effect of FTY720 on chronic cyclosporine nephropathy in rats.
Kim JY; Lim SW; Li C; Kim JS; Ahn KO; Yang HJ; Choi BS; Kim YS; Kim J; Bang BK; Yang CW
Transplantation; 2005 Nov; 80(9):1323-30. PubMed ID: 16314802
[TBL] [Abstract][Full Text] [Related]
11. Reduction of ischemia-reperfusion injury in the rat kidney by FTY720, a synthetic derivative of sphingosine.
Delbridge MS; Shrestha BM; Raftery AT; El Nahas AM; Haylor JL
Transplantation; 2007 Jul; 84(2):187-95. PubMed ID: 17667810
[TBL] [Abstract][Full Text] [Related]
12. Cytoprotective Actions of FTY720 Modulate Severe Preservation Reperfusion Injury in Rat Renal Transplants.
Fuller TF; Hoff U; Kong L; Naether M; Wagner P; Nieminen-Kelhä M; Nolting J; Luft FC; Hegner B; Dragun D
Transplantation; 2010 Feb; 89(4):402-8. PubMed ID: 20177341
[TBL] [Abstract][Full Text] [Related]
13. Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2006 Jan; 290(1):F167-76. PubMed ID: 16048904
[TBL] [Abstract][Full Text] [Related]
14. FTY720 in combination with cyclosporine--an analysis of skin allograft survival and renal function.
Silva FR; Silva LB; Cury PM; Burdmann EA; Bueno V
Int Immunopharmacol; 2006 Dec; 6(13-14):1911-8. PubMed ID: 17161344
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
Krämer S; Loof T; Martini S; Rückert M; Wang Y; Böhler T; Shimizu F; Kawachi H; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
[TBL] [Abstract][Full Text] [Related]
16. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
[TBL] [Abstract][Full Text] [Related]
17. [Effect of FTY720 on glomerulosclerosis and expression of cell cycle regulatory proteins in subtotally nephrectomized rats].
Zhu GQ; Zhou JH; Xie M; Hao Y
Zhonghua Er Ke Za Zhi; 2007 Dec; 45(12):922-6. PubMed ID: 18339282
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of FTY720 on chronic allograft nephropathy by reducing late lymphocytic infiltration.
Wang M; Liu S; Ouyang N; Song E; Lutz J; Heemann U
Kidney Int; 2004 Sep; 66(3):1248-56. PubMed ID: 15327424
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
Roos M; Liu S; Strobl M; Schmaderer C; Baumann M; Heemann U; Lutz J
Transplant Proc; 2008 Dec; 40(10):3731-6. PubMed ID: 19100477
[TBL] [Abstract][Full Text] [Related]
20. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Nofer JR; Bot M; Brodde M; Taylor PJ; Salm P; Brinkmann V; van Berkel T; Assmann G; Biessen EA
Circulation; 2007 Jan; 115(4):501-8. PubMed ID: 17242282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
